Cellectar Biosciences, Inc. is a company headquartered in the United States.
Cellectar Biosciences develops targeted cancer therapies using its Phospholipid Drug Conjugate (PDC) platform to deliver therapeutic agents directly to tumor cells, aiming to maximize antitumor activity while minimizing off-target effects.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.